J&J back in court over recalled hips; Becton Dickinson snags software outfit;

 @FierceMedDev: Stryker slapped with FDA warning letter. More | Follow @FierceMedDev

 @MarkHFierce: St. Jude Medical is releasing a next-gen stent imaging system in Japan, hoping to propel major interest. Article | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics IPO target keeps falling, from $41.9M to $29.3M to $20.1M and, now, just $14.3M. Report | Follow @DamianFierce

> With one $8.3 million verdict in the can, Johnson & Johnson ($JNJ) is back to the courtroom for its second all-metal hip trial. Article

> A major South Africa medical device trade group argues many of its members won't be able to achieve the government's proposed "codes of good practice" for the country's black economic empowerment zones. Story

> Fresh off its $48 million funding round, 2012 Fierce 15 winner Nevro has completed enrollment in its pivotal trial for Senza. Item

> Following an expanded CE mark, Medtronic's ($MDT) Resolute stent demonstrated that it can prevent patients from serious blood clot risk even if they interrupt dual antiplatelet therapy after 30 days. More

> Critical Diagnostics unveiled study results demonstrating that its Presage ST2 Assay succeeds in identifying patients who would benefit from high-dose beta blockers, a possible enticement for a companion diagnostics deal. News

> Becton Dickinson ($BDX) has snatched up Cato Software Solutions, which makes software to assist with pharmacy prep of intravenous medications, physician therapy planning and nursing-related bedside documentation. Release

> Researchers found that patients who had heart bypass surgery minus a heart-lung machine did as well 12 months later as patients who used the device during their own procedures. Release

Biotech News

 @FierceBiotech: In case you missed it: Medtronic, Edwards headline this year's ACC news. Roundup | Follow @FierceBiotech

 @JohnCFierce: Another high flying cancer drug developer looks like a takeover. Puma turns Pfizer castoff into gold. Report | Follow @JohnCFierce

 @RyanMFierce: Shire has acquired Premacure AB for drug against rare eye disease. Release | Follow @RyanMFierce

> Analysts cheer decision to continue Merck's controversial Vytorin study. Article

> Puma Biotech shares roaring up amid M&A meow. Story

> Astellas dumps $390M pact with Ambit on eve of IPO. News

> Omthera files $75M IPO as it blueprints omega-3 drug launch. More

Pharma News

 @FiercePharma: That Novartis probe is responding to criminal complaints about lack of disclosure, per BloombergMore | Follow @FiercePharma

 @EricPFierce: Baxter Intl. investing more into international manufacturing, this time in Puerto Rico but it means 400 fewer jobs. Article | Follow @EricPFierce

> ProPublica: Pharma's doc-payment disclosures top $2B. Article

> Swiss prosecutor weighs charges against Novartis directors, ex-chairman. News

> Merck gets green light to continue Vytorin outcomes trial. More

Pharma Manufacturing News

> Marken pushes international expansion with warehouse in China. Item

> Pfizer, Glaxo, others give Interpol money to fight counterfeiters. Report

> Catalent deals target China from 2 directions. Story

Biotech Research News

 @EmilyMFierce: The origin of ovarian cancer has evaded scientists, but researchers at Cornell may have found a possible source. More | Follow @EmilyMFierce

> New therapy shows promise in treating inflammatory breast cancer. Report

> Deleting a gene in mice prevents obesity. Article

> Salt may be risk factor for MS, other autoimmune diseases. Story

> Buildup of unwanted proteins may lead to dementia. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.